BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-616@pharmaconomics
DTSTAMP:20260707T033206Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:AXSM Phase 2 — solriamfetol (estimated date)
DESCRIPTION:Phase 2 trial results for solriamfetol in attention deficit hyperactivity disorder (ADHD) are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/616
URL:https://pharmaconomics.com/e/616
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AXSM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR